>> Continued From the Previous Page <<
Critics argue the change would allow European, Chinese, and Indian companies to line up generic versions of patented American drugs while U.S. firms are still legally protected. Once patents expire, those competitors could flood the market immediately, cutting deeply into the revenues that fund future medical breakthroughs.
Former Ohio Congressman Brad Wenstrup sounded the alarm in a recent op-ed that quickly gained traction among conservative policymakers.
“These changes would undermine international obligations to respect patents and enable European, Chinese, and Indian companies to prepare and seek to commercialize generic versions of medicines while American patents remain in effect,” Wenstrup wrote.
The concern is not abstract. Developing a single new drug routinely costs American companies more than $2 billion when accounting for research, testing, and regulatory approval. Those investments are largely recouped through the U.S. market, which generates roughly 78 percent of global pharmaceutical profits.
Europe, by contrast, relies on government-controlled health systems that aggressively suppress drug prices. Many countries impose caps, delay approvals, or block medicines entirely unless manufacturers agree to steep discounts. As a result, Americans often pay several times more for the same prescriptions sold overseas.
That imbalance has long been a source of frustration in Washington. But the EU’s latest proposal is viewed by many as crossing a new line.
The United States already runs a roughly $250 billion trade deficit with the European Union. On top of that, American consumers pay about three times as much for prescription drugs as patients in France, Germany, Italy, Spain, and the United Kingdom.
When Wenstrup’s warning circulated online, reaction was swift.
Alex Bruesewitz, an adviser to President Trump, blasted the proposal in blunt terms.
“Pretty shocking given that Europe wants us to fund all of their national defense,” Bruesewitz wrote.
“They are trying to push through a regulatory change that would allow them to take advantage of our patented innovations,” he continued. “That’s unacceptable.”
Others echoed the sentiment. Market commentator Wall Street Mav explained the issue in simple terms that resonated with conservative audiences.
“Europe gets vastly cheaper drug prices, with Americans paying 3x more for name-brand drugs that are still under patent protection,” he wrote. “The EU just allows their companies to make cheap generics, forcing Americans to carry the R&D costs and pay for it all.”
“Once again, the socialists in the EU expect the USA to pay for everything while they get a free ride,” he added. “Using the hammer of tariffs, President Trump is forcing changes in US-EU trade talks.”
Unlike previous administrations, President Trump has already demonstrated a willingness to confront this imbalance directly. His team recently reached a landmark agreement with the United Kingdom requiring higher payments for new medicines. Under the deal, the UK agreed to raise what it pays for innovative drugs by 25 percent and limit rebate schemes that quietly claw prices back down.
In exchange, the U.S. exempted British pharmaceuticals from Section 232 tariffs and agreed not to target UK pricing practices under Section 301 investigations.
Trump administration officials say the EU has not shown similar willingness to reform.
Commerce Secretary Howard Lutnick has confirmed that Section 232 investigations into pharmaceutical imports are underway, with Section 301 probes into foreign pricing practices also on the table. Tariffs remain a real possibility.
Online, conservative frustration continues to build.
“Why is Europe constantly undermining America?” wrote X user Declaration of Memes. “We basically defend and protect them at a HUGE cost to American taxpayers. Do we get thanked? No, instead we get constantly undermined.”
“When it comes to patents, predominantly intellectual property and pharmaceutical patents, the EU continues to take advantage of America,” he added.
President Trump has been clear that the era of American consumers subsidizing the world is coming to an end. Brussels’ latest maneuver may only accelerate that reckoning.
